200 related articles for article (PubMed ID: 7813575)
1. Thrombolytic efficacy of a modified tissue-type plasminogen activator, SUN9216, in the rat middle cerebral artery thrombosis model.
Umemura K; Toshima Y; Nakashima M
Eur J Pharmacol; 1994 Sep; 262(1-2):27-31. PubMed ID: 7813575
[TBL] [Abstract][Full Text] [Related]
2. Effect of combination of a tissue-type plasminogen activator and an endothelin receptor antagonist, FR139317, in the rat cerebral infarction model.
Umemura K; Ishiye M; Kosuge K; Nakashima M
Eur J Pharmacol; 1995 Feb; 275(1):17-21. PubMed ID: 7774658
[TBL] [Abstract][Full Text] [Related]
3. A simple and reproducible cerebral thrombosis model in rats induced by a photochemical reaction and the effect of a plasminogen-plasminogen activator chimera in this model.
Matsuno H; Uematsu T; Umemura K; Takiguchi Y; Asai Y; Muranaka Y; Nakashima M
J Pharmacol Toxicol Methods; 1993 Jun; 29(3):165-73. PubMed ID: 8364230
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the combination of a tissue-type plasminogen activator, SUN9216, and a thromboxane A2 receptor antagonist, vapiprost, in a rat middle cerebral artery thrombosis model.
Umemura K; Wada K; Uematsu T; Nakashima M
Stroke; 1993 Jul; 24(7):1077-81; discussion 1081-2. PubMed ID: 8322383
[TBL] [Abstract][Full Text] [Related]
5. Thrombolytic effect of a plasminogen-plasminogen activator chimera in a photochemically induced thrombosis (PIT) model.
Matsuno H; Uematsu T; Nakashima M
Br J Pharmacol; 1993 Dec; 110(4):1278-9. PubMed ID: 8306063
[TBL] [Abstract][Full Text] [Related]
6. Effect of dietary docosahexaenoic acid in the rat middle cerebral artery thrombosis model.
Umemura K; Toshima Y; Asai F; Nakashima M
Thromb Res; 1995 Jun; 78(5):379-87. PubMed ID: 7660354
[TBL] [Abstract][Full Text] [Related]
7. A new rat model of thrombotic focal cerebral ischemia.
Zhang Z; Zhang RL; Jiang Q; Raman SB; Cantwell L; Chopp M
J Cereb Blood Flow Metab; 1997 Feb; 17(2):123-35. PubMed ID: 9040491
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of thrombolytic efficacy of tissue-type plasminogen activator by adjuvants in the guinea pig thrombosis model.
Nishiyama H; Umemura K; Saniabadi AR; Takiguchi Y; Uematsu T; Nakashima M
Eur J Pharmacol; 1994 Oct; 264(2):191-8. PubMed ID: 7851482
[TBL] [Abstract][Full Text] [Related]
9. Tissue-type plasminogen activator improves neurological functions in a rat model of thromboembolic stroke.
Sakurama T; Kitamura R; Kaneko M
Stroke; 1994 Feb; 25(2):451-6. PubMed ID: 8303756
[TBL] [Abstract][Full Text] [Related]
10. The effect of intravenous tissue-type plasminogen activator in a rat model of embolic cerebral ischemia.
Penar PL; Greer CA
Yale J Biol Med; 1987; 60(3):233-43. PubMed ID: 3111108
[TBL] [Abstract][Full Text] [Related]
11. Effect of intra-arterial tissue plasminogen activator and urokinase on autologous arterial emboli in the cerebral circulation of rabbits [corrected].
Benes V; Zabramski JM; Boston M; Puca A; Spetzler RF
Stroke; 1990 Nov; 21(11):1594-9. PubMed ID: 2122553
[TBL] [Abstract][Full Text] [Related]
12. The Kringle-2 domain of tissue plasminogen activator significantly reduces mortality and brain infarction in middle cerebral artery occlusion rats.
Zhang H; Bi F; Xiao C; Liu J; Wang Z; Liu JN; Zhang J
Int J Mol Med; 2010 Aug; 26(2):225-30. PubMed ID: 20596602
[TBL] [Abstract][Full Text] [Related]
13. Effect of the duration of middle cerebral artery occlusion on the risk of hemorrhagic transformation after tissue plasminogen activator injection in rats.
Copin JC; Gasche Y
Brain Res; 2008 Dec; 1243():161-6. PubMed ID: 18835259
[TBL] [Abstract][Full Text] [Related]
14. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
[TBL] [Abstract][Full Text] [Related]
15. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.
Collen D; Stassen JM; Yasuda T; Refino C; Paoni N; Keyt B; Roskams T; Guerrero JL; Lijnen HR; Gold HK
Thromb Haemost; 1994 Jul; 72(1):98-104. PubMed ID: 7974384
[TBL] [Abstract][Full Text] [Related]
16. Photochemically induced thrombosis model in rat femoral artery and evaluation of effects of heparin and tissue-type plasminogen activator with use of this model.
Matsuno H; Uematsu T; Nagashima S; Nakashima M
J Pharmacol Methods; 1991 Jul; 25(4):303-17. PubMed ID: 1909407
[TBL] [Abstract][Full Text] [Related]
17. Recombinant Tissue Plasminogen Activator-conjugated Nanoparticles Effectively Targets Thrombolysis in a Rat Model of Middle Cerebral Artery Occlusion.
Deng J; Mei H; Shi W; Pang ZQ; Zhang B; Guo T; Wang HF; Jiang XG; Hu Y
Curr Med Sci; 2018 Jun; 38(3):427-435. PubMed ID: 30074208
[TBL] [Abstract][Full Text] [Related]
18. [Direct continuous observation of in situ thrombolysis in the cerebral embolic model of rabbits].
Kashiwabara S; Kurokawa Y; Uede T; Hashi K
No To Shinkei; 1998 Apr; 50(4):347-54. PubMed ID: 9592824
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human tissue-type plasminogen activator therapy in acute thromboembolic stroke.
Papadopoulos SM; Chandler WF; Salamat MS; Topol EJ; Sackellares JC
J Neurosurg; 1987 Sep; 67(3):394-8. PubMed ID: 3112328
[TBL] [Abstract][Full Text] [Related]
20. Reperfusion after thrombolytic therapy of embolic stroke in the rat: magnetic resonance and biochemical imaging.
Busch E; Krüger K; Allegrini PR; Kerskens CM; Gyngell ML; Hoehn-Berlage M; Hossmann KA
J Cereb Blood Flow Metab; 1998 Apr; 18(4):407-18. PubMed ID: 9538906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
